ArticleArtificial organs2026
Incidence and Management of Access Site Infection Following Trans-Axillary Implant of a Microaxial Left Ventricular Assist Device.
Article in Artificial organs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Impella 5.5 is microaxial left ventricular assist device (LVAD) implanted most commonly into the axillary artery (AxA). This study aims to investigate the incidence and management of vascular graft infection (VGI) following circulatory support with the Impella 5.5.
methodsThis is a single-center retrospective analysis of 92 patients who were supported by Impella 5.5 between June 2020 and August 2024. Since November 2023, Dacron graft has been tunneled through the pectoralis major muscle via a separate incision in patients expected to require prolonged support. The graft was trimmed and buried beneath the pectoralis major muscle during explant. Support period was classified as short (≤ 14 days, Group SS) or extended (> 14 days, Group ES).
resultsOf the 92 patients, 26 (28.3%) died while on support, Impella was explanted in 66 patients (71.7%): Bridge-to-recovery in 36 (39.1%), bridge-to-durable LVAD in 8 (8.7%), and bridge-to-transplant in 22 (23.4%) including 5 heart and kidney transplant (HKT). Median support duration was 7 [5, 8] days in Group SS (N = 54) and 27.5 [18, 38] days in Group ES (N = 38). No infections were reported in Group SS. Four patients in Group ES who underwent HKT experienced VGI following 39, 47, 51, and 85 days of support. Two patients with tunneled grafts required patch repair of AxA, while the remaining two patients with non-tunneled grafts required extensive extra-anatomical bypass.
conclusionApproximately 10% of patients requiring extended support developed VGI. Heart transplant recipients with a high risk of infection such as extended support or HKT will benefit from a comprehensive approach for early diagnosis and therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.